Table 2 Comparison of baseline and follow-up characteristics between HIV-infected patients with and without co-infection of tuberculosis in propensity score matched pairs with imputed covariates (for a single multiple imputation dataset)
Covariate | TB: yes | TB: no | Standardized difference |
|---|---|---|---|
|  | (n = 1686) | (n = 1686) | (Ratio of variance for continuous covariate) |
Baseline characterstics | |||
Demographics | |||
Age (year) | Â | Â | Â |
  Mean (SD) | 36.89 (8.77) | 36.93 (8.87) | −0.005 (0.978) |
  Min | 14 | 14 | |
  25th percentile | 31 | 31 | |
  50th percentile | 36 | 36 | |
  75th percentile | 42 | 42 | |
  Max | 73 | 77 | |
Male: n (%) | 668 (39.62) | 673 (39.92) | −0.006 |
HIV severity | |||
CD4 count | Â | Â | Â |
  Mean (SD) | 143.70 (149.98) | 144.34 (139.78) | −0.004 (1.15) |
  Min | 0 | 0 |  |
  25th percentile | 45 | 44 | |
  50th percentile | 112 | 118 | |
  75th percentile | 194 | 196 | |
  Max | 1701 | 1247 | |
WHO stage: n (%) | Â | Â | Â |
  1 | 43 (2.55) | 43 (2.55) | - |
  2 | 441 (26.16) | 436 (25.86) | |
  3 | 996 (59.07) | 983 (58.30) | |
  4 | 206 (12.22) | 224 (13.29) | |
AIDS: n (%) | 489 (29.00) | 479 (28.41) | 0.013 |
History of drug use & illnesses: n (%) | |||
Pneumocystis pneumonia | 25 (1.48) | 33 (1.96) | −0.037 |
Toxoplasmosis | 11 (0.65) | 8 (0.47) | 0.024 |
Sexually transmitted infection | 340 (20.17) | 339 (20.11) | 0.001 |
Partner information: n (%) | |||
Married poly | 125 (7.41) | 136 (8.07) | −0.024 |
Partner sero-positive | 417 (24.73) | 431 (25.56) | −0.019 |
Sexually active | 1221 (72.42) | 1223 (72.54) | −0.003 |
Other characteristics: n (%) | |||
Site | Â | Â | Â |
  ENT | 374 (22.18) | 378 (22.42) | - |
  GUL | 161 (9.55) | 176 (10.43) | |
  JIN | 276 (16.37) | 271 (16.07) | |
  MAS | 130 (7.71) | 125 (7.41) | |
  MBL | 144 (8.54) | 160 (9.49) | |
  MBR | 116 (6.88) | 121 (7.18) | |
  MSD | 61 (3.62) | 62 (3.68) | |
  MUL | 211 (12.51) | 203 (12.04) | |
  SOR | 29 (1.72) | 18 (1.07) | |
  TOR | 184 (10.91) | 172 (10.20) | |
Education (Higher institute) | 58 (3.44) | 59 (3.50) | −0.003 |
ART start year since 2000 | Â | Â | Â |
  4 | 23 (1.36) | 15 (0.89) | - |
  5 | 452 (26.81) | 428 (25.39) | |
  6 | 372 (22.06) | 360 (21.35) | |
  7 | 505 (29.95) | 548 (32.50) | |
  8 | 330 (19.57) | 330 (19.57) | |
  9 | 4 (0.24) | 5 (0.30) | |
Follow-up characteristics | |||
Death: n (%) | 176 (10.44) | 137 (8.13) | 0.080 |
Median (IQR) length of follow-up (days) | 629 (205–1036) | 659 (286–1023) | - |